Clinical trials: Neurodevelopmental Disorder
Attention Deficit Disorder With Hyperactivity
Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD
Evaluate the behavioral effects of MTS in children aged 6-12 with ADHD
- Trial name
- NCT00466791
- Testing
- Methylphenidate Transdermal System
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Noven Therapeutics
Attention Deficit Hyperactivity Disorder
Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the efficacy, safety and to assess the impact of the treatment on quality of life of long-acting methylphenidate in adult participants with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT00783835
- Testing
- Long-Acting Methylphenidate
- Where
- 5 sites in Brazil
- Volunteers
- 60 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Autism
An Open Label Study of CM-AT for the Treatment of Children With Autism
This is a Phase III, open label extension study evaluating the continued safety and efficacy of CM-AT in pediatric patients with autism with all levels of fecal chymotrypsin.
- Trial name
- NCT02649959
- Testing
- CM-AT
- Where
- 31 sites in United States
- Volunteers
- 405 people
- Sponsor
- Curemark
Attention Deficit Hyperactivity Disorder
ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder
This is a randomized, double-blind, flexible dose-titration, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of ADZENYS XR-ODT compared to placebo in children with ADHD.
- Trial name
- NCT07169162
- Testing
- ADZENYS XR-ODT
- Where
- United States
- Sponsor
- Aytu BioPharma, Inc.
Aphasia, Global, Stroke
tDCS and Speech Therapy to Improve Aphasia
To study the effect of combined tDCS plus speech therapy compared to sham-tDCS plus speech therapy in subacute stroke patients suffering from moderate or severe aphasia.
- Conditions
- Aphasia, Global, Stroke, Transcranial Direct Current Stimulation, Speech Therapy
- Trial name
- MP-LOGA (NCT02395874)
- Testing
- tDCS + speech therapy
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- Medical Park AG
Autism Spectrum Disorder
Cognoa ASD Diagnosis Aid Validation Study
The primary objective of this study is to collect data to ascertain the Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of the current version of the Cognoa diagnostic device.
- Trial name
- NCT04151290
- Testing
- Cognoa ASD diagnostic device
- Where
- 16 sites in United States
- Volunteers
- 711 people
- Sponsor
- Cognoa, Inc.
Attention Deficit Hyperactivity Disorder
Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant
The purpose of this study is to determine the effects of combining AKL-T01 (with AKL-X01 symptom tracking) as adjunctive treatment to stimulant medication, and to understand the effects of AKL-T01 treatment (with AKL-X01 symptom…
- Trial name
- NCT03649074
- Testing
- AKL-T01
- Where
- 2 sites in United States
- Volunteers
- 206 people
- Sponsor
- Akili Interactive Labs, Inc.
ADHD
Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study
The primary objective of this study is to evaluate the long-term safety of LDX administered as a daily morning dose (30, 50, and 70 mg/day) in the treatment of adolescents (13-17 years of age inclusive at the time of consent).
- Trial name
- NCT00764868
- Testing
- Lisdexamfetamine Dimesylate (LDX)
- Where
- 45 sites in United States
- Volunteers
- 269 people
- Sponsor
- Shire
Attention-deficit Hyperactivity Disorder (ADHD)
Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder
This trial is a Phase 1 study in adolescents with ADHD and genetic disruptions impacting genes in the metabotropic glutamate receptor (mGluR) network.
- Trial name
- NFC1-GREAT (NCT02286817)
- Testing
- NFC-1
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
The aim of the iSPOT-A study is to: 1. identify brain, genetic and cognitive markers of Attention Deficit/Hyperactivity Disorder, and 2.
- Trial name
- NCT00863499
- Testing
- Short Acting Methylphenidate, Long Acting Methylphenidate
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 1,344 people, healthy volunteers welcome
- Sponsor
- BRC Operations Pty. Ltd.
Attention Deficit Hyperactivity Disorder
A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The primary objectives are to investigate the effect of atomoxetine on impulsivity after single dose and at steady state measured by the total score of Barrett Impulsiveness Scale version 11 (BIS-11) and Short Urgency…
- Trial name
- NCT05278104
- Testing
- Zentiva®
- Where
- 5 sites in Germany
- Volunteers
- 63 people
- Sponsor
- Boehringer Ingelheim
ADHD
Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD
An 8-week, Open-Label Study to Characterize the Response to Modafinil (85mg Film-Coated Tablet) Treatment at Dosages up to 425mg/Day in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) (With an…
- Trial name
- NCT00228540
- Testing
- Modafinil
- Where
- 39 sites in United States
- Sponsor
- Cephalon
Tourette's Syndrome
Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years
Tourette's Syndrome is a neurological disease characterized by motor and vocal tics. It has been hypothesized that abnormal interactions of dopamine with its receptors may cause the tics.
- Trial name
- NCT02102698
- Testing
- Ecopipam
- Where
- 11 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emalex Biosciences Inc.
Attention Deficit Disorder With Hyperactivity
Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17
The purpose of this study is to determine the effects of SPD503 compared to placebo on tasks of sustained attention in children and adolescents aged 6-17 diagnosed with ADHD.
- Trial name
- NCT00150592
- Testing
- SPD503 (Guanfacine HCl)
- Volunteers
- 182 people
- Sponsor
- Shire
Developmental and Epileptic Encephalopathy
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed…
- Trial name
- NCT06908226
- Testing
- LP352
- Where
- 88 sites in United States, Australia and 15 more
- Volunteers
- 324 people
- Sponsor
- Longboard Pharmaceuticals
Attention Deficit Hyperactivity Disorder
PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations
This is PART B of a 2-part, 6-week, double-blind, dose-optimization, parallel-group study in children and adolescents (ages 6-17 years) with ADHD with and without CNVs in specific genes implicated in glutamatergic signaling and…
- Trial name
- NCT03609619
- Testing
- AEVI-001
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Tourette Syndrome
A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
This is an open-label study of SNC-102 (acamprosate calcium sustained release tablet) in adult subjects with Tourette Syndrome. Subjects will be treated with oral doses of SNC-102 800 mg on a BID basis - before breakfast and at…
- Trial name
- NCT02217007
- Testing
- SNC-102 sustained release tablet
- Where
- 2 sites in United States
- Sponsor
- Synchroneuron Inc.
Sleep Disorders, Neurodevelopmental Disorder
Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
The purpose of this study is to evaluate the efficacy on sleep latency with electronic sleep diaries and the safety of NPC-15.
- Trial name
- NPC-15-6 (NCT02757079)
- Testing
- NPC-15
- Volunteers
- 99 people
- Sponsor
- Nobelpharma
Attention Deficit Hyperactivity Disorder (ADHD)
PRC-063 in an ADULT Workplace Environment
The primary objective of this study is to assess the time of onset and time course of efficacy over 16 hours of PRC-063 compared to placebo in adults diagnosed with ADHD in a simulated adult workplace environment (AWE) setting…
- Trial name
- NCT02225639
- Testing
- PRC-063 25 mg, PRC-063 35 mg, PRC-063 45 mg
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Tic Disorder, Tourette Syndrome
Phase III Study of 5LGr to Treat Tic Disorder
The purpose of this study is to evaluate the effective and safety of 5LGr in pediatric patients with tic disorders.
- Conditions
- Tic Disorder, Tourette Syndrome, Chronic Tic Disorder
- Trial name
- 5LGr (NCT01501695)
- Testing
- 5LGr, tiapride
- Volunteers
- 603 people
- Sponsor
- Tasly Pharmaceuticals, Inc.